Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy

Table 4 Univariable associations of infarct size determined by various methods with 90-day mortality

Method	COMMA trial		COMPLY trial
Method	Hazard ratio (95% CI)	Wald χ ²(P value)	Hazard ratio (95% CI)	Wald χ 2 (P value)
Total CK-MB AUC, 0 to 72 hours from randomization estimated by curve modeling^a
per 1000 units	1.07	2.76	1.09	26.05
per 1000 units	(0.99 to 1.17)	(0.10)	(1.06 to 1.13)	(<0.01)
per 1 SD	1.35		1.58
per 1 SD	(0.95 to 1.92)		(1.33 to 1.88)
Estimated peak^a
per 100 units	1.02	0.76	1.12	16.41
per 100 units	(0.98 to 1.07)	(0.38)	(1.06 to 1.19)	(<0.01)
per 1 SD	1.10		1.41
per 1 SD	(0.89 to 1.36)		(1.20 to 1.67)
Observed trapezoidal CK-MB AUC
per 1000 units	1.09	4.61	1.10	29.04
per 1000 units	(1.01 to 1.19)	(0.03)	(1.06 to 1.14)	(<0.01)
per 1 SD	1.45		1.62
per 1 SD	(1.03 to 2.03)		(1.36 to 1.93)
Observed peak
per 100 units	1.16	3.75	1.13	16.26
per 100 units	(1.00 to 1.34)	(0.05)	(1.06 to 1.19)	(<0.01)
per 1 SD	1.41		1.41
per 1 SD	(1.00 to 2.00)		(1.19 to 1.66)

^aEstimated from the log-normal model. AUC, area under the curve; CI, confidence interval; CK, creatine kinase; COMMA, COMplement inhibition in Myocardial infarction treated with Angioplasty; COMPLY, COMPlement inhibition in myocardial infarction treated with thromboLYtics; SD, standard deviation.

ISSN: 1745-6215